VNDA Stock News 10.78 05/13/2014 18:19:03 Vanda Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vanda Pharmaceuticals Inc (VNDA) 10.78 $VNDA

Nasdaq stocks posting largest percentage decreases
AP - Fri May 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:

Vanda Pharmaceuticals Down 25.2% Since SmarTrend Downtrend Call (VNDA)
Comtex SmarTrend(R) - Fri May 09, 9:16AM CDT
SmarTrend identified a Downtrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on April 11th, 2014 at $13.69. In approximately 4 weeks, Vanda Pharmaceuticals has returned 25.17% as of today's recent price of $10.24.

Health Care Stocks to Watch Today: Amarin Corporation plc, Jazz Pharmaceuticals, and Vanda Pharmaceu
George Budwell, The Motley Fool - Motley Fool - Fri May 09, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Amarin ,  Jazz Pharmaceuticals and  Vanda Pharmaceuticals .   Amarin reports first-quarter earnings The much-maligned biotech Amarin reported...

Vanda Pharmaceuticals Reports First Quarter 2014 Results
PR Newswire - Thu May 08, 6:00AM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2014.

Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.

Today's Dead Cat Bounce Stock: Vanda Pharmaceuticals (VNDA)
at The Street - Mon Apr 28, 9:15AM CDT
Trade-Ideas LLC identified Vanda Pharmaceuticals (VNDA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Vanda Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 8, 2014
PR Newswire - Thu Apr 24, 4:30PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the first quarter of 2014 on Thursday, May 8, 2014, before the market opens.

Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free

Vanda Pharmaceuticals Announces Availability of HETLIOZ(TM) (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)
PR Newswire - Wed Apr 09, 6:00PM CDT
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.

Vanda Pharmaceuticals Shares Up 22.5% Since SmarTrend's Buy Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 08, 11:10AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 22.53% as of today's recent price of $15.31.

Vanda Pharmaceuticals Has Returned 33.8% Since SmarTrend Recommendation (VNDA)
Comtex SmarTrend(R) - Tue Apr 01, 9:43AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 33.81% as of today's recent price of $16.72.

Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews

Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

41.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)
Comtex SmarTrend(R) - Tue Mar 25, 9:18AM CDT
SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 41.74% as of today's recent price of $17.71.

Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 3:25PM CDT
You might be compelled to think that territorial tensions between Russia and Ukraine and generally mixed economic data might push the market lower, but you'd be sorely mistaken. In fact, new highs are outpacing new lows by close to a 10-to-1 margin...

Breakfast Round-up - 52-Weeks High Reset: NextEra Energy, Silver Standard Resources, Wisconsin Energy, and Vanda Pharma
PR Newswire - Tue Mar 18, 8:39AM CDT
On Monday, March 17, 2014, the NASDAQ Composite finished at 4,279.95, up 0.81%. The Dow Jones Industrial Average closed the session at 16,247.22, up 1.13% and the S&P 500 ended the day at 1,858.83, higher by 0.96%. The gains were broad based as all the sectors ended the session in positive. Investor-Edge.com looks at some of the equities that hit a new 52-week high during the last session. These include NextEra Energy Inc. (NYSE:NEE), Silver Standard Resources Inc. (NASDAQ:SSRI), Wisconsin Energy Corporation (NYSE MKT: WEC), and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Free research on these four companies can be accessed at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 55

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 0

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 159

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 11

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 72

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading

Top 5 Most Recently Viewed Articles

IASO Bio Achieves Major Milestone with Orphan Drug Status

Updated Category News Views 270

IASO Bio Earns Orphan Drug Designation for Breakthrough Therapy IASO Biotherapeutics, a key player in the biopharmaceutical sector, announced an exciting achievement as its groundbreaking treatment, Equecabtagene Autoleucel (Fucaso), received Orphan Drug Designation from the Ministry of Food and Drug Safety. This recognition is particularly significant for adults fighting...

Continue Reading
Transforming Experience: Honda Center's $1 Billion Revamp

Updated Category News Views 387

Transforming Experience: Honda Center's $1 Billion Revamp Honda Center Encore Is A Multi-Year Investment Led by the Samueli Family That Will Redefine the Arena Experience OC Sports & Entertainment (OCSE), connected with the operator of Honda Center, has announced a groundbreaking project known as Honda Center Encore. This ambitious venture involves a significant...

Continue Reading
PIMCO Municipal Income Fund Faces Market Pressures at New Lows

Updated Category News Views 192

PIMCO Municipal Income Fund's Recent Market Performance PIMCO Municipal Income Fund (PMF) has recently faced significant market challenges, as evidenced by its stock hitting a notable 52-week low at a price of $8.82. This decline isn't merely an isolated incident; it reflects ongoing pressures impacting the broader fixed-income sector. Investors are currently navigating...

Continue Reading
Exploring Non-Surgical Solutions for Prostate Health Issues

Updated Category News Views 174

Prostate health became a hot topic for many men over 50, especially with the rise of benign prostatic hyperplasia (BPH)—that uncomfortable enlargement that turns bathroom trips into sprints. Back then, treatment options were shaking up, and PAE was coming onto the scene like it owned the place. PAE vs. Traditional Surgery: The Fight for Relief In an era where...

Continue Reading
Applied Digital Appoints Laura Laltrello as COO for AI Growth

Updated Category News Views 245

Applied Digital Names Laura Laltrello as New COO Applied Digital Corporation (NASDAQ: APLD) is excited to announce the appointment of Laura Laltrello as its new Chief Operating Officer (COO). With an aim to strengthen the Company’s leadership in next-generation data centers and digital cloud solutions, Ms. Laltrello's role signifies a pivotal moment in the Company’s...

Continue Reading